Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
elderly group:covid-19 inactivated vaccine
Sponsors
the Fifth Medical Center of the Chinese People's Liberation Army General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. The new crown vaccine is planned; 2. Elderly subjects aged 60-80 and young and middle-aged subjects aged 18 to 59 years; 3. The subjects can and are willing to comply with the requirements of the clinical trial protocol, complete the 12-month study follow-up and sign the informed consent; 4. HBsAg, anti HCV, HIV and TPHA screening were negative; 5. The new crown RNA test was negative; 6. Axillary body temperature <=37.0 degree C.
Exclusion criteria
Exclusion criteria: 1. Women with positive urine pregnancy test, women who are pregnant, breastfeeding, or women who plan to become pregnant within 6 months; 2. Suffering from a serious chronic disease or the disease is in a progressive stage and cannot be controlled smoothly, such as diabetes, asthma, thyroid disease, etc. that cannot be controlled by drugs; 3. Suffering from thrombocytopenia, bleeding disorders or thrombotic disorders; 4. Suffering from more serious cardiovascular diseases, such as arrhythmia, conduction block, myocardial infarction, severe hypertension that cannot be controlled by drugs, etc.; 5. Suffering from congenital or acquired angioedema/neurotic edema; 6. History or family history of convulsions, epilepsy, encephalopathy, other progressive neurological diseases and psychiatric diseases; 7. Suffering from lymphoma, leukemia and other systemic malignant tumors; 8. Suffering from autoimmune diseases; 9. Those with fainting needles; 10. Has received immunosuppressive therapy, antiallergic therapy, cytotoxic therapy, or inhaled corticosteroids in the past 6 months (excluding corticosteroid spray therapy for allergic rhinitis, and surface corticosteroid therapy for acute non-complicated dermatitis); 11. Received blood products within 4 months before receiving the experimental vaccine; 12. Received other research drugs within 1 month before receiving the experimental vaccine; 13. Receive other types of vaccines within 1 month before receiving the experimental vaccine; 14. Patients with acute exacerbation of chronic diseases or acute infectious diseases and fever.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 2019 neutralizing antibody against New Coronavirus; | — |
Countries
China
Contacts
Public ContactWang Fusheng
The Fifth Medical Center of Chinese People's Liberation Army General Hospital
Outcome results
None listed